Prognostic evaluation of high sensitivity-C reactive protein in non-Hodgkin lymphoma
10.3969/j.issn.1000-8179.20130176
- VernacularTitle:超敏C反应蛋白对非霍奇金淋巴瘤的预后评估作用
- Author:
Lijun SHI
;
Lin CHEN
;
Chenjiao ZHOU
- Publication Type:Journal Article
- Keywords:
non-Hodgkin lymphoma;
high sensitivity-C reactive protein;
prognostic evaluation
- From:
Chinese Journal of Clinical Oncology
2013;(22):1382-1386
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate high sensitivity-C reactive protein (Hs-CRP) as a prognostic factor in non-Hodgkin lympho-ma (NHL). Methods:Data for 85 consecutive non-Hodgkin lymphoma patients were followed up and reviewed to determine the value of Hs-CRP relative to known prognostic parameters. Results:The progression-free survival (PFS) and overall survival (OS) times of pa-tients with pre-therapeutic baseline serum Hs-CRP levels of≥4 mg/L were shorter than those of patients with basal serum Hs-CRP lev-els of<4 mg/L (P>0.05). However, the post-therapeutic, early-to-mid serum Hs-CRP level was not significantly correlated with the OS and PFS times (P>0.05). Multivariate Cox regression analysis showed that the pre-therapeutic baseline serum Hs-CRP level may be an important prognostic parameter for the relapse and survival of NHL patients (P<0.05). Conclusion:The baseline Hs-CRP level can be a major indicator of prognosis in NHL patients.
